A recent study published in Blood (November 2024) presents results from the Phase 3 inMIND trial, evaluating the addition of tafasitamab to lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL).
The findings demonstrate that adding tafasitamab significantly improved progression-free survival (PFS) compared to placebo, with a 57% reduction in the risk of progression, relapse, or death. The combination also showed higher overall response and complete response rates, reinforcing its potential as a new treatment standard for R/R FL. Safety was manageable, aligning with expected toxicities.
These results highlight a promising advance in lymphoma treatment, particularly through the combination of two monoclonal antibodies (anti-CD19 and anti-CD20) alongside immunomodulatory therapy.
Thank you to all the researchers involved in this important work!
For more details, refer to the study published in Blood:https://lnkd.in/e7SGkh8J
